JP2015514115A5 - - Google Patents

Download PDF

Info

Publication number
JP2015514115A5
JP2015514115A5 JP2015504730A JP2015504730A JP2015514115A5 JP 2015514115 A5 JP2015514115 A5 JP 2015514115A5 JP 2015504730 A JP2015504730 A JP 2015504730A JP 2015504730 A JP2015504730 A JP 2015504730A JP 2015514115 A5 JP2015514115 A5 JP 2015514115A5
Authority
JP
Japan
Prior art keywords
pharmaceutical preparation
polypeptide
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015504730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514115A (ja
JP6234993B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/035305 external-priority patent/WO2013152213A1/en
Publication of JP2015514115A publication Critical patent/JP2015514115A/ja
Publication of JP2015514115A5 publication Critical patent/JP2015514115A5/ja
Application granted granted Critical
Publication of JP6234993B2 publication Critical patent/JP6234993B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015504730A 2012-04-06 2013-04-04 赤血球を増加させるための方法および組成物 Expired - Fee Related JP6234993B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621154P 2012-04-06 2012-04-06
US61/621,154 2012-04-06
PCT/US2013/035305 WO2013152213A1 (en) 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017144654A Division JP2017190344A (ja) 2012-04-06 2017-07-26 赤血球を増加させるための方法および組成物

Publications (3)

Publication Number Publication Date
JP2015514115A JP2015514115A (ja) 2015-05-18
JP2015514115A5 true JP2015514115A5 (enExample) 2016-06-02
JP6234993B2 JP6234993B2 (ja) 2017-11-22

Family

ID=49301055

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015504730A Expired - Fee Related JP6234993B2 (ja) 2012-04-06 2013-04-04 赤血球を増加させるための方法および組成物
JP2017144654A Withdrawn JP2017190344A (ja) 2012-04-06 2017-07-26 赤血球を増加させるための方法および組成物
JP2019123059A Withdrawn JP2019156858A (ja) 2012-04-06 2019-07-01 赤血球を増加させるための方法および組成物
JP2021077695A Pending JP2021107453A (ja) 2012-04-06 2021-04-30 赤血球を増加させるための方法および組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017144654A Withdrawn JP2017190344A (ja) 2012-04-06 2017-07-26 赤血球を増加させるための方法および組成物
JP2019123059A Withdrawn JP2019156858A (ja) 2012-04-06 2019-07-01 赤血球を増加させるための方法および組成物
JP2021077695A Pending JP2021107453A (ja) 2012-04-06 2021-04-30 赤血球を増加させるための方法および組成物

Country Status (6)

Country Link
US (4) US9809636B2 (enExample)
EP (2) EP3351260B1 (enExample)
JP (4) JP6234993B2 (enExample)
AU (3) AU2013243388B2 (enExample)
CA (1) CA2869474C (enExample)
WO (1) WO2013152213A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
SG11201707815RA (en) 2015-06-05 2017-12-28 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
EP3370754B1 (en) 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
CA2108770C (en) 1991-06-25 2007-04-03 John M. Wozney Bmp-9 compositions
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
CA2157387C (en) * 1993-03-04 1998-12-15 David C. Rueger Method and compositions for recombinant osteogenic protein production
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
ATE265529T1 (de) 1993-05-12 2004-05-15 Inst Genetics Llc Bmp-10 zusammensetzungen
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
JP2008534607A (ja) * 2005-03-30 2008-08-28 ワイス Bmpを投与することによって毛髪の成長を刺激するための方法
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
CA2672758C (en) 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
TWI584815B (zh) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 活化素-ActRIIa拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
MX2009008510A (es) 2007-02-09 2010-01-15 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
CN105963695A (zh) 2008-05-02 2016-09-28 阿塞勒隆制药公司 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物
EP2291401A2 (en) 2008-05-15 2011-03-09 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
KR20110031951A (ko) 2008-06-26 2011-03-29 악셀레론 파마 인코포레이티드 액티빈-actriia의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
KR102170682B1 (ko) 2009-08-13 2020-10-28 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 gdf 트랩과 에리트로포이에틴 수용체 활성인자의 병용
JP2012238811A (ja) 2011-05-13 2012-12-06 Toshiba Corp 半導体不揮発性記憶装置およびその製造方法
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CA2874117C (en) * 2012-07-02 2021-10-12 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia
TWI814187B (zh) 2015-05-13 2023-09-01 美商西建公司 使用ACTRII配位體捕捉以治療β-地中海型貧血

Similar Documents

Publication Publication Date Title
JP2017533910A5 (enExample)
Merten et al. Viral vectors for gene therapy and gene modification approaches
JP2015518818A5 (enExample)
JP2014512171A5 (enExample)
JP2014513952A5 (enExample)
JP2016501528A5 (enExample)
JP2015520161A5 (enExample)
JP2015508771A5 (enExample)
JP2015517488A5 (enExample)
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
FI3310809T3 (fi) Anti-cgrp-vasta-aineformulaatio
RU2015128078A (ru) Композиции и способы лечения рака мозга
JP2014503206A5 (enExample)
JP2016539946A5 (enExample)
WO2015138357A3 (en) Compositions useful in treatment of otc deficency
JP2016538885A5 (enExample)
JP2016506416A5 (enExample)
JP2012529436A5 (enExample)
WO2013059559A3 (en) Compounds and methods for enhancing innate immune responses
JP2013136622A5 (enExample)
JP2017532343A5 (enExample)
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
JP2016517421A5 (enExample)
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same